Enhertu granted Priority Review for breast cancer
17 January 2022 07:00 GMT Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Based on ground-breaking DESTINY-Breast03 results showing AstraZeneca and Daiichi Sankyo's Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) Application being evaluated under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (